Tag: nasdaq:rckt

March 11, 2020

Forty Seven and Rocket Collaborate for Fanconi Anemia Research

Forty Seven and Rocket have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel conditioning regimen...
March 5, 2020

Rocket Pharmaceuticals Reports Full Year 2019 Financial Results

Rocket reports financial results for the year ended December 31, 2019, and provides an update on the company's recent pipeline...
October 16, 2019

Biotech Market Update: Q3 2019 in Review

With Q3 2019 officially over, the Investing News Network shares a biotech market update on the biggest news and trends...
September 10, 2019

Rocket Pharmaceuticals Announces Data from Phase 1/2 Trial of RP-L102

Rocket Pharmaceuticals (NASDAQ:RCKT) has announced the publication of long-term data from its ongoing Phase 1/2 trial of RPL-102, the company’s...
November 19, 2018

Rocket Pharmaceuticals Receives FDA Drug Clearance

The company’s drug, PR-L201, is in development to treat Leukocyte Adhesion Deficiency-I, a rare pediatric disease.
November 19, 2018

Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy

Rocket Pharmaceuticals (Nasdaq:RCKT) a leading U.S.-based multi-platform gene therapy company, announces the clearance of the Company’s Investigational New Drug (IND) application...